Created with Sketch.
New Retina Radio by Eyetube
20 minutes | Aug 4, 2022
ASRS Meeting Coverage: Day 2
Was treat-and-extend faricimab (Vabysmo, Genentech) an effective means of controlling DME in the YOSEMITE and RHINE studies? New Retina Radio spoke with John Kitchens, MD, whose ASRS presentation reviewed results from a pair of phase 3 studies that assessed, in part, 12- and 16-week dosing intervals of faricimab in patients with DME. Also joining us is Michael Allingham, MD, PhD. He shared results from the phase 2b ZETA-1 study, which examined the safety and efficacy of APX3330 (Ocuphire Pharma), an oral medication for DR. What promise might this treatment hold? Tune in to learn more. This editorially independent podcast is supported with advertising.
26 minutes | Jul 28, 2022
ASRS Meeting Coverage: Day 1
Treat-and-extend regimens has been used for thousands of wet AMD patients. How does brolucizumab (Beovu, Novartis) stack up when compared with aflibercept (Eylea, Regeneron) in a matched treat-and-extend study? New Retina Radio spoke with Carl Regillo, MD, a member of the TALON study group, which sought to find out if brolucizumab was superior to aflibercept for extending treatment intervals in wet AMD patients. We also spoke with Carl Danzig, MD, whose work on the TRUCKEE study illuminates real-world treatment dynamics when it comes to the use of faricimab (Vabysmo, Genentech) in wet AMD treatment. How are patients responding in the real world?
26 minutes | Jul 14, 2022
New Retina Radio Journal Club: Recurrent RRD Management
How might two recent contributions to the literature deepen our understanding of recurrent rhegmatogenous retinal detachment (RRD)? To find out, moderator Kyle Kovacs, MD, is joined by panelists Cynthia Qian, MD, and David Xu, MD, to review a pair of papers on the topic. After the break, the group tackles tamponade selection and use of scleral buckles in patients with RRD, and discusses tactics for bringing a patient back to the OR if RRD recurs. This editorially independent podcast is supported with advertising.
74 minutes | Jun 30, 2022
The Life and Career of Steve Charles, MD, FACS, FICS, FASRS
In this episode, John W. Kitchens, MD, speaks with Steve Charles, MD, FACS, FICS, FASRS, a vitreoretinal surgeon and founder of the Charles Retina Institute in Germantown, Tennessee, as well as clinical professor of ophthalmology at the University of Tennessee in Memphis. Known to many as the architect behind the ACCURUS and CONSTELLATION from Alcon, his career is wildly impressive, but Dr. Kitchens finds his life and career history even more fascinating. This podcast is editorially independent.
20 minutes | Jun 23, 2022
New Retina Radio Journal Club: Pentosan Polysulfate Maculopathy
What are the latest findings regarding pentosan poloysulfate maculopathy (PPM)? Moderator Basil Williams, MD, invites panelists Karen Jeng-Miller, MD, MPH; M. Ali Khan, MD; and Katherine Talcott, MD, to review two recent publications seeking to better characterize the condition After the break, the discussion turns to the utility of imaging modalities in PPM management and an exploration into hospital-based policies that might lead to earlier detection of PPM in patients undergoing a new course of pentosan polysulfate sodium therapy.
19 minutes | Jun 9, 2022
ARVO Meeting Coverage Day 3: CANDELA and ARCHWAY Data
Could an 8-mg dose intensify the therapeutic effect of aflibercept (Eylea, Regeneron) in patients with wet AMD? The phase 2 CANDELA study sought to explore the safety and efficacy of high-dose aflibercept in this patient population. What did Dave Brown, MD, and his research colleagues observe? And 96-week data from ARCHWAY are in. Did the complete study, which reached its primary endpoint after 40 weeks, reveal new data that could affect clinical decision-making when it comes to real-world use of the Port Delivery System with Ranibizumab (Susvimo, Genentech)? Hear our interview with Robert Mittra, MD, to find out. This editorially independent podcast is supported with advertising.
24 minutes | Jun 2, 2022
ARVO Meeting Coverage Day 2: Pipeline Therapies in GA
Could RPE cell replacement therapy be the future of GA treatments? Retina Today’s Chief Medical Editor Allen C. Ho, MD, joined us to discuss observations from a phase 1/2a study evaluating the safety and efficacy of OpRegen (Lineage Cell Therapeutics), a suspension of allogenic RPE cells implanted in the subretinal space. How well was this therapy tolerated, and were there any signs of vision improvement? Elsewhere in the GA pipeline, researchers are exploring whether the gene therapy GT005 (Gyroscope Therapeutics) might be a safe and effective one-time treatment for GA via upregulation of complement factor I. How does complement factor I affect the course of GA, and what are the latest data from a phase 1/2 study? Check out this episode to hear on conversation on that topic with Jared Nielsen, MD, MBA. This podcast is editorially independent, supported with advertising.
32 minutes | May 26, 2022
ARVO Meeting Coverage Day 1: LIGHTSITE III and DERBY/OAKS at 18 Months
Could photobiomodulation soon be a therapeutic option for patients with dry AMD? Researchers in the LIGHTSITE III study are working toward finding out. We spoke with Marion Munk, MD, PhD, about the details from a study that evaluated the Valeda Light Delivery System (LumiThera) in patients with dry AMD. Were patients able to safely realize any improvement to visual function? And we checked in with Roger Goldberg, MD, MBA, who detailed the 18-month findings of the DERBY and OAKS studies, a pair of phase 3 clinical trials evaluating the safety and efficacy of pegcetacoplan (APL-2, Apellis Pharmaceuticals) in patients with geographic atrophy. The studies’ primary endpoint was at 1 year. What did they find after an additional 6 months? Stick here to find out.
35 minutes | May 19, 2022
New Treatment Options and Considerations for AMD
Anti-VEGF therapy has been a game changer for patients with AMD; now, the treatment toolbox is getting an overhaul with two new approvals and, hopefully, more on the way. Allen C. Ho, MD, sat down with Robyn Guymer AM, MBBS, PhD, FRANZCO, FAHMS; Charles C. Wykoff, MD, PhD; and Diana V. Do, MD, to discuss how these new treatments are going to change clinical practice and how to educate patients on the pros and cons of each option.
17 minutes | May 12, 2022
New Retina Radio Journal Club: Trends in Retina Reimbursement
How has reimbursement for common vitreoretinal procedures changed from 2011 to 2020? To find out, moderator Eric Nudleman, MD, PhD, hears from panelists John Miller, MD; Thanos Papakostas, MD; and Priya Vakharia, MD, as they discuss a recent piece on the topic published in the journal Ophthalmology. After reviewing the findings, the panel discusses the implications for reduced reimbursement in an era of improved efficiency and asks whether future innovation will allow patients to receive the same level of care even as reimbursement declines.
24 minutes | Apr 21, 2022
New Retina Radio Journal Club: Diversity in Clinical Trials
Do the demographics of patients enrolled in clinical trials accurately reflect the patient populations their drugs intend to treat? Moderator Basil Williams, MD, is joined by panelists Karen Jeng-Miller, MD, MPH; M. Ali Khan, MD, and Katherine Talcott, MD, to summarize a pair of papers exploring this topic. After summarizing the papers' findings, the group reviews a phase 4 trial seeking to enroll underrepresented patients and asks which barriers to enrollment may be linked to shortcomings in demographic diversity.
30 minutes | Mar 31, 2022
New Retina Radio Journal Club: PPV vs PnR for RRD
Pars plana vitrectomy (PPV) and pneumatic retinopexy (PnR) are both commonly employed to repair rhegmatogenous retinal detachment (RRD). What does the literature have to say about the safety and outcomes of these two procedures? Moderator Eric Nudleman, MD, PhD, asks panelists John Miller, MD; Thanos Papakostas, MD; and Priya Vakharia, MD, to break down the PIVOT and ALIGN studies, both of which were recently published in the journal Ophthalmology Retina. What were these studies’ findings—and how accurately do they reflect clinical experience?
28 minutes | Mar 24, 2022
Art of Drug Choice: Treating New Wet AMD Patients
Have innovations in therapy actually led to a paradigm shift when it comes to encountering patients with newly diagnosed wet AMD? In the season finale of “The Art of Drug Choice,” moderator Arshad M. Khanani, MD, MA, is joined by panelists Lejla Vajzovic, MD, and Joseph M. Coney, MD, to review strategies for treating new wet AMD patients, to discuss where new technologies fit into a treatment algorithm, and to examine the best time to switch patients to a new therapeutic option. After the break, Dr. Khanani updates the panel on a patient case shared in previous seasons of this series, which involves a patient with a 12-year treatment history who experienced significant vision loss following a change in therapy. How did Dr. Khanani manage the case—and what happened after inflammation was brought under control? This editorially independent podcast is supported with advertising.
26 minutes | Mar 17, 2022
Art of Drug Choice: Who Is Best Suited for Extended-duration Therapy?
How do retina specialists decide which wet AMD patients are best suited for extended duration therapy and which patients should continue with more traditional intervention? In the second episode of this season of “The Art of Drug Choice,” moderator Arshad M. Khanani, MD, MA, asks Lejla Vajzovic, MD, and Joseph M. Coney, MD, about which factors they weigh most heavily when determining if a patient could be a good candidate for a change in treatment strategy, and discuss how gene therapy may play a role in wet AMD treatment. After the break, Dr. Vajzovic reviews the case of a patient who has undergone treatment with three different anti-VEGF agents. Why and when did she switch this patient to a different therapy? This editorially independent podcast is supported with advertising.
27 minutes | Mar 3, 2022
Art of Drug Choice: The Latest Advances in Wet AMD Therapy
How have the most recent advances in wet AMD therapy changed the treatment landscape for clinicians? In this debut episode of the third season of “The Art of Drug Choice,” moderator Arshad M. Khanani, MD, MA, is joined by Lejla Vajzovic, MD, and Joseph M. Coney, MD, for a discussion about choosing patients who are best suited for the recently approved therapies, and for a preview of how biosimilars could affect treatment decisions. After the break, Dr. Coney shares the case of a patient whose need to extend treatment intervals was addressed by switching to a new anti-VEGF agent. This editorially independent podcast is supported with advertising.
33 minutes | Feb 24, 2022
Anti-VEGF, A Biography: Part 3
This story started in the early days of VEGF's isolation in the 1970s and brought us to the discovery of ranibizumab and bevacizumab in the mid 2000s. The data revealed at the ASRS meeting in 2005 would change retina forever-and usher in a new competitor with a chance to disrupt the landscape yet again. Don't miss the final episode of this fascinating and important story told by those that lived it. We're bringing back some of the voices you've heard before, and some new ones, too. John D. Pitcher III, MD, invites Bob Avery, MD; David Brown, MD; Jeffrey Heier, MD; Nancy Holekamp, MD; Kirk Packo, MD; Phillip Rosenfeld, MD, PhD; and Bob Vitti, MD, to tell the latest chapter of anti-VEGF's biography. This editorially independent podcast is supported with advertising.
34 minutes | Feb 17, 2022
Anti-VEGF, A Biography: Part 2
New Retina Radio continues its biography of anti-VEGF. John D. Pitcher III, MD, picks up the story where we left off: in a world where pegaptanib was the only intravitreal injection approved for treating wet AMD. But a deep dive into the literature and a few calculations on the back of a napkin are about to change retina practice forever. Guests in this episode include Bob Avery, MD; Dave Brown, MD; Anne Fung, MD; Jeffrey Heier, MD; Andrew Moshfeghi, MD, MBA; Kirk Packo, MD; and Philip Rosenfeld, MD, PhD. This editorially independent podcast is supported with advertising.
32 minutes | Feb 11, 2022
Exploring the clinical development program for an innovative, continuous delivery treatment for nAMD
Recently, the first refillable, intraocular device that enables continuous delivery of therapy was FDA approved for nAMD. John Kitchens, MD sits down with one of the investigators, Dante Pieramici, MD, to learn more about his experiences with the clinical development program and this innovative drug delivery system. This special episode of New Retina Radio is supported by Genentech USA, Inc., which is responsible for its content.
35 minutes | Feb 3, 2022
Tackling PVR in the OR
In this roundtable moderated by Allen C. Ho, MD, and Robert L. Avery, MD, experts discuss the frustration of postoperative proliferative vitreoretinopathy and strategies to minimize its incidence in the clinic. Panelists include Dean Eliott, MD; Avni P. Finn, MD, MBA; Ajay Kuriyan, MD, MS; and M. Ali Khan, MD. This podcast is editorially independent.
31 minutes | Jan 27, 2022
Anti-VEGF, A Biography: Part 1
Many young retina specialists have always known retina as an anti-VEGF world. But how did this happen? John D. Pitcher III, MD, joins Scott and Ranna in studio to deliver the first part of the tale of anti-VEGF in retina, taking the story back to the 1970s to tell the story of the discovery of VEGF, the creation of pegaptanib, and the struggles that early anti-VEGF encountered in retina. There are a lot of guests for this one, but the major players for this episode are Tony Adamis, MD; Bob Avery, MD; Jeff Heier, MD; and Kirk Packo, MD. This editorially independent podcast is supported with advertising.
Terms of Service
Do Not Sell My Personal Information
© Stitcher 2022